Economic Evaluation of a Booster Dose of TDaP Vaccine to Adolescents in Spain
Author(s)
Ewa Pawlowska Pawlowska, PhD1, María-José Faraldo Vallés, MPH1, Janet Puñal-Rioboo, MPH1, Paula Guadalupe Cantero Muñoz 000000000000000000000000000000, MPH1, Ignacio José López-Loureiro, PhD1, Margarita Franco Sanmartín, MPH2.
1Galician Agency for Health Knowledge Management (ACIS), Santiago de Compostela, Spain, 2Galician Health Service (SERGAS), Santiago de Compostela, Spain.
1Galician Agency for Health Knowledge Management (ACIS), Santiago de Compostela, Spain, 2Galician Health Service (SERGAS), Santiago de Compostela, Spain.
OBJECTIVES: In 2023 and 2024, there was a significant increase in pertussis cases in Spain, despite high vaccination coverage rates: 98.2% primary vaccination with the paediatric tetanus, diphtheria, and pertussis vaccine (DTaP) and 88.5% with the adult vaccine (Tdap) in pregnant women. In 2024, 30,982 cases were reported, resulting in nearly 540 hospitalisations and 5 deaths. The vast majority, 63.9% of pertussis cases, occurred in children under 15 years, with the highest incidence in the 10-14 age group. The re-emergence of pertussis disease calls for a reconsideration of current vaccination strategies. We aim to explore the economic aspects of systematic vaccination of adolescents, 11-14 years old, with a booster dose of Tdap.
METHODS: We carried out a systematic bibliographic search in general and health economic-specific databases of cost-effectiveness studies on the administration of a booster dose of the Tdap vaccine to adolescents, as a first step toward economic evaluation. This was complemented by targeted search to identify recent recommendations for adolescents pertussis vaccination schedules.
RESULTS: Initial findings suggest that dynamic transmission models should be preffered in order to asses the cost-effectiveness of adolescent immunization strategies. In order to be useful to the decision makers, the correct time horizon should include a short and medium term cost and effect analysis. Herd immunity, the incidence and the severity are some crucial parameters to be considerd. Most of the EU countries as well as Australia, Canada and USA have included a Tdap dose in their adolescent vaccination schedules.
CONCLUSIONS: According WHO recommendations, the introduction of boosters should be guided by local epidemiology and cost-effectiveness data. Given the epidemiological evolution of pertussis, the inclusion of a booster dose of the Tdap vaccine for adolescents in the Spanish vaccination schedule should be supported by high-quality evidence on the cost-effectiveness of pertussis immunization alternative strategies.
METHODS: We carried out a systematic bibliographic search in general and health economic-specific databases of cost-effectiveness studies on the administration of a booster dose of the Tdap vaccine to adolescents, as a first step toward economic evaluation. This was complemented by targeted search to identify recent recommendations for adolescents pertussis vaccination schedules.
RESULTS: Initial findings suggest that dynamic transmission models should be preffered in order to asses the cost-effectiveness of adolescent immunization strategies. In order to be useful to the decision makers, the correct time horizon should include a short and medium term cost and effect analysis. Herd immunity, the incidence and the severity are some crucial parameters to be considerd. Most of the EU countries as well as Australia, Canada and USA have included a Tdap dose in their adolescent vaccination schedules.
CONCLUSIONS: According WHO recommendations, the introduction of boosters should be guided by local epidemiology and cost-effectiveness data. Given the epidemiological evolution of pertussis, the inclusion of a booster dose of the Tdap vaccine for adolescents in the Spanish vaccination schedule should be supported by high-quality evidence on the cost-effectiveness of pertussis immunization alternative strategies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE372
Topic
Economic Evaluation, Epidemiology & Public Health, Health Technology Assessment
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines